Pomalyst® (pomalidomide): New important advice to minimise the risk of serious hepatotoxicity, interstitial lung disease and cardiac failure

Celgene Pte Ltd, Singapore, would like to inform healthcare professionals of important new safety information regarding Pomalyst® (pomalidomide). A European review concluded that pomalidomide can cause serious hepatotoxicity (acute hepatitis), interstitial lung disease and cardiac failure. The safety review was based on data from clinical trials, reports from clinical practice as well as published case reports. The local Package Insert and Patient Information Leaflet for Pomalyst® will be updated to include the above-mentioned newly identified risks. Please refer to the letter for more information.
Healthcare professional, Therapeutic Products
Published:

Dear Healthcare Professional Letters

12 Dec 2019

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.hpp.moh.gov.sg/, and follow the procedures below to access the MOH Alert system.

Step 1: Scroll down to the bottom navigation panel of the HPP web page. Under the Healthcare Professionals section, expand the dropdown option for ‘Healthcare Professional Portal’ and select your profession. You will be redirected to the specific HPP web page to log in.

Step 2: Click on the Restricted Content icon on the left panel of the web page and log in via SingPass.

Step 3: Click on the MOH Alert icon under the ‘Applications’ section.

Step 4: Click on the Drug Alert tab to view the DHCPLs.